JNJan Nouta

Jan Nouta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jan Nouta has a total of 4 co-authors. Here are the top co-authors by number of shared publications:

  • Peter G. Scheffer

    Metabolic Laboratory, Department of Clinical Chemistry, VU University Medical Center, Amsterdam, The Netherlands

    1 shared publication
  • Roberto S. G. M. Perez

    Department of Anesthesiology, VU University Medical Center, 6F002, De Boelelaan 1117, 1081HV Amsterdam, The Netherlands

    1 shared publication
  • Sigrid G. L. Fischer

    Department of Anesthesiology, VU University Medical Center, Amsterdam, The Netherlands; EMGO Institute for Health and Care Research (EMGO+), Amsterdam, The Netherlands; Knowledge Consortium Trauma Related Neural Dysfunction (TREND), Leiden, The Netherlands

    1 shared publication
  • Wouter Wa Zuurmond

    Department of Anesthesiology, VU University Medical Center, Amsterdam, the Netherlands

    1 shared publication

Latest Publications

  • Open Access

    Oxidative Stress in Complex Regional Pain Syndrome (CRPS): No Systemically Elevated Levels of Malondialdehyde, F2-Isoprostanes and 8OHdG in a Selected Sample of Patients

    by Sigrid G. L. Fischer, Roberto S. G. M. Perez, Jan Nouta, Wouter W. A. Zuurmond, Peter G. Scheffer

    Exaggerated inflammation and oxidative stress are involved in the pathogenesis of Complex Regional Pain Syndrome (CRPS). However, studies assessing markers for oxidative stress in CRPS patients are limited. In this study, markers for lipid peroxidation (malondialdehyde and F2-isoprostanes) and DNA damage (8-hydroxy-2-deoxyguanosine) were measured in nine patients (mean age 50.1 ± 17.1 years) with short term CRPS-1 (median 3 months) and nine age and sex matched healthy volunteers (mean age 49.3 ± 16.8 years) to assess and compare the level of oxidative stress. No differences were found in plasma between CRPS patients and healthy volunteers for malondialdehyde (5.2 ± 0.9 µmol/L vs. 5.4 ± 0.5 µmol/L) F2-isoprostanes (83.9 ± 18.7 pg/mL vs. 80.5 ± 12.3 pg/mL) and 8-hydroxy-2-deoxyguanosine (92.6 ± 25.5 pmol/L vs. 86.9 ± 19.0 pmol/L). Likewise, in urine, no differences were observed between CRPS patients and healthy volunteers for F2-isoprostanes (117 ng/mmol, IQR 54.5–124.3 vs. 85 ng/mmol, IQR 55.5–110) and 8-hydroxy-2-deoxyguanosine (1.4 ± 0.7 nmol/mmol vs. 1.4 ± 0.5 nmol/mmol). Our data show no elevation of systemic markers of oxidative stress in CRPS patients compared to matched healthy volunteers. Future research should focus on local sampling methods of oxidative stress with adequate patient selection based on CRPS phenotype and lifestyle.